Swedish Orphan Profile

20.40
USD 15.05  281.59%
100%
0%

Swedish Orphan Summary

Swedish Orphan Biovitrum AB (BIOVF) is traded on OTC Market in USA. It is located in Tomtebodav?gen 23A and employs 816 people. The company currently falls under 'Mid-Cap' category with current market capitalization of 5.62 B. Swedish Orphan Biovitrum AB has 269.12 M outstanding shares. SWEDISH ORPHAN BI has accumulated about 208.48 M in cash with 153.31 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.77.
Check Swedish Orphan Probability Of Bankruptcy

Target Price Odds Analysis

Odds Below 20.4HorizonTargetOdds Above 20.4
?%30 days 20.40 ?%
Based on normal probability distribution, the odds of Swedish Orphan to move above current price in 30 days from now is about 0.0% (This Swedish Orphan Biovitrum AB probability density function shows the probability of Swedish Orphan Stock to fall within a particular range of prices over 30 days) .

Top Holders

Key Fundamentals

Swedish Orphan Against Markets

Current Ratings

Swedish Orphan 30 Days Performance Scores
Risk Adjusted
Performance Score (0 to 100)
9 
Chance of
Financial Distress (0 to 100%)
44 
Equity ratings for Swedish Orphan Biovitrum AB are calculated dynamically based on Macroaxis scoring framework. Click here to learn more
Swedish Orphan Biovitrum AB , an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haemophilia, inflammation, and genetic and lysosomal diseases. Swedish Orphan Biovitrum AB is headquartered in Solna, Sweden. Swedish Orphan is traded on OTC Market in USA. more
NameSwedish Orphan Biovitrum AB
CEOGeoffrey McDonoughView All
Macroaxis Advice
InstrumentUSA Stock View All
Business AddressTomtebodav?gen 23A
ExchangeOTC Market
SectorHealthcare
BenchmarkDOW
Websitewww.sobi.com
Contact Number46 86 97 20 00
CurrencyUSD - US Dollar

Diversify with Swedish Orphan Biovitrum AB

Build Optimal Portfolios
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Swedish Orphan Biovitrum AB to your portfolio

Directors

Swedish Orphan Corporate Directors
Hans Wigzell Independent Director, Ph.D
Lennart Johansson Director, MBA
Annette Clancy Independent Director
Check also Trending Equities. Please also try Balance Of Power module to check stock momentum by analyzing balance of power indicator and other technical ratios.